The characters shown are real patients and the required consent to use their stories has been obtained from the patients and families. Photographs are for illustrative purposes only.
Two experts in neuromuscular disease shared their latest insights and perspectives on assessing and treating patients with SMA.
In this session, Prof. Sansone presented recent insights on the importance of swallowing function as a key consideration for patients with SMA and the need to measure it with equal importance as respiratory function.
In this session, Prof. Servais discussed ‘what matters’ in type 1 SMA, and highlighted the importance of setting appropriate treatment expectations for motor function in this patient group.
Prof. Valeria Sansone
NeuroMuscular Omnicentre (NEMO)
Prof. Laurent Servais
Muscular Dystrophy UK (MDUK), MDUK Oxford Neuromuscular Centre University of Oxford, Oxford, UK and University of Liege Liege, Belgium
Which genes are responsible for the SMA phenotype? Learn from Dr. Eduardo Tizzano about how SMA is a disease involving two genes.
Several motor function scales have been developed that are useful in quantifying the natural history of spinal muscular atrophy (SMA).1-3 Learn about the importance of measuring the progression of the disease.
Learn more about Biogen's participation in
ICNMD and Neurology events.
Check out the Biogen-sponsored symposia, publications and posters about SMA from this and other past congresses at: SMA scientific lounge
1. Glanzman AM, et al. The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord 2010;20(3):155-161.
2. De Sanctis R., et al. Developmental milestones in type I spinal muscular atrophy, Neuromuscular Disorders. Volume 26, Issue 11, 2016, 754-759.
3. Mercuri E, et al. Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials. Neuromuscul Disord 2016;26(2):126-131.